Celldex Therapeutics Inc. (CLDX)

3.18
NASDAQ : Health Technology
Prev Close 3.11
Day Low/High 3.11 / 3.23
52 Wk Low/High 2.75 / 11.62
Avg Volume 434.90K
Exchange NASDAQ
Shares Outstanding 13.77M
Market Cap 42.82M
EPS -14.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings

Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings

Shares of Celldex Therapeutics (CLDX) were up in afternoon trading Tuesday after the company's drug Rintega received breakthrough designation therapy from the U.S. Food and Drug Administration on Monday.

Celldex Reports Fourth Quarter And Year-End 2014 Results

Celldex Reports Fourth Quarter And Year-End 2014 Results

Conference Call Scheduled for 8:00 a.m. ET Today

Celldex Therapeutics (CLDX) Weak On High Volume Today

Celldex Therapeutics (CLDX) Weak On High Volume Today

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Traders Are Placing Long-Term Bets on Celldex Therapeutics

Traders Are Placing Long-Term Bets on Celldex Therapeutics

Traders place long-term bets on Celldex Therapeutics, bucking the broad market downturn.

Six Biotech and Technology Stocks With Strong Technical Set-Ups

Six Biotech and Technology Stocks With Strong Technical Set-Ups

Wednesday's session featured some good moves and technical set-ups, particularly in biotech and technology.

Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)

Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

An Unproductive Day in the Markets

It ended with many stocks and indices stuck within broad range boundaries.

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Celldex Therapeutics (CLDX) Stock Rises Today on High Volume

Celldex Therapeutics (CLDX) Stock Rises Today on High Volume

Shares of Celldex Therapeutics (CLDX) soared in early afternoon trading Thursday on higher-than-average volume.

Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains

Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains

Shares of Celldex Therapeutics (CLDX) dipped Tuesday after the stock surged Monday following the company's announcement of positive results of its immunotherapy in treating a certain type of brain tumor.

Perilous Reversal Stock: Celldex Therapeutics (CLDX)

Perilous Reversal Stock: Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results

Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results

Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.

Heavy Early Morning Activity On Celldex Therapeutics (CLDX)

Heavy Early Morning Activity On Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a pre-market mover with heavy volume candidate

Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients

Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients

Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.

Celldex Presents Varlilumab Proof Of Concept Data At SITC Annual Meeting 2014

Celldex Presents Varlilumab Proof Of Concept Data At SITC Annual Meeting 2014

Favorable safety profile, clear biological effects and clinical activity position varlilumab for future studies

Celldex Therapeutics (CLDX) Stock Drops on Change in Phase 3 Enrollment Criteria

Celldex Therapeutics (CLDX) Stock Drops on Change in Phase 3 Enrollment Criteria

Celldex Therapeutics (CLDX) shares are down despite beating analysts' quarterly expectations due to changes in its phase 3 enrollment criteria and wider quarterly losses.

Celldex Therapeutics Shares Fall on Breast Cancer Study Changes

Celldex Therapeutics Shares Fall on Breast Cancer Study Changes

Investors are selling Celldex today because of concerns the changes made to the METRIC study of CDX-011 introduce more risk

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: Celldex Therapeutics (CLDX)

Strong On High Volume: Celldex Therapeutics (CLDX)

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

TheStreet Quant Rating: D- (Sell)